United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,480,600.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total value of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00.

United Therapeutics Price Performance

NASDAQ UTHR opened at $353.31 on Wednesday. The business has a fifty day moving average price of $362.06 and a two-hundred day moving average price of $358.24. United Therapeutics Co. has a fifty-two week low of $210.64 and a fifty-two week high of $417.82. The stock has a market capitalization of $15.78 billion, a PE ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on UTHR shares. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. HC Wainwright boosted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $382.08.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics during the fourth quarter worth $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics during the third quarter worth $33,000. Millstone Evans Group LLC bought a new stake in United Therapeutics during the fourth quarter worth $67,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics during the third quarter worth $82,000. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.